Yes, pharma companies can use AI for promotional materials — but the answer comes with significant caveats. AI can accelerate content production, support personalisation at scale, and reduce time spent on early-stage drafting. The challenge is that pharmaceutical promotion operates within some of the most tightly governed regulatory frameworks in the world, and AI introduces new accountability questions those frameworks were not designed to address. The sections below work through the most pressing practical and strategic questions that pharma marketing and medical affairs teams are grappling with in 2026.
What are the regulatory risks of using AI in pharma promotion?
The core risks centre on accuracy, balance, and accountability. AI models can generate content that sounds plausible but is factually incorrect, omit required safety information, overstate efficacy, or produce claims that have not been reviewed against the approved label. In regulated markets, any of these failures can constitute a code breach or a regulatory violation — regardless of how the content was produced.
In the UK, promotional materials for prescription medicines must comply with the ABPI Code of Practice. In the US, the FDA’s Office of Prescription Drug Promotion governs pharmaceutical advertising. Both frameworks require that promotional content is accurate, balanced, not misleading, and consistent with the approved prescribing information. AI systems trained on broad datasets do not inherently know where those boundaries sit for a specific product in a specific market.
There are also risks specific to how AI generates language. Large language models can produce confident-sounding statements that are not grounded in approved data, blend information from different products or therapeutic areas, or apply claims from clinical trial subgroups to broader populations. Without robust human review at every stage, these errors can reach final materials. The regulatory risk is not that AI is being used — it is that AI output is being trusted without adequate scrutiny.
How does AI actually generate pharma promotional content?
AI generates pharma promotional content primarily through large language models (LLMs) that predict contextually appropriate text based on a given prompt and their training data. In a pharmaceutical context, a user typically provides a brief, a product description, or a set of approved claims, and the model produces a draft following the structural and stylistic patterns it has learned from similar content.
More sophisticated implementations use retrieval-augmented generation (RAG), where the AI is connected to a curated library of approved documents — such as the Summary of Product Characteristics (SmPC), approved claims matrices, or medical information databases — and draws on those sources when generating output. This approach reduces the risk of hallucinated or off-label claims because the model is anchored to verified content rather than relying solely on its training data.
Some platforms designed specifically for pharmaceutical marketing add a further layer: pre-configured guardrails that flag content falling outside approved language or automatically trigger a medical, legal, and regulatory (MLR) review workflow. Even with these tools, the output is a starting point for human review, not a finished promotional piece. The generation process is fast; the governance process that must follow it is not.
What types of pharma promotional tasks is AI best suited for?
AI delivers the most value in tasks that are high-volume, structurally repetitive, or require adaptation of approved content across formats and audiences — rather than original claim development. The strongest use cases involve working within an already-approved content framework, not creating one from scratch.
- Content modularisation: Breaking approved long-form materials into shorter, channel-appropriate modules for digital, sales force, or patient-facing use
- Localisation and adaptation: Adapting approved global materials for local markets, adjusting language, regulatory references, and formatting
- First-draft copy: Generating initial drafts of detail aids, emails, or congress abstracts from approved claims for human review and refinement
- Metadata and tagging: Organising and categorising content libraries to improve retrieval and reuse
- Audience segmentation copy: Creating variations of approved messaging for different HCP specialties or patient profiles
- Competitive landscape summaries: Synthesising published literature or market data to support strategy development (not for direct promotional use)
Where AI is least suited is in the creation of novel claims, the interpretation of clinical data for promotional purposes, or any content requiring original scientific judgement. These tasks demand medical and regulatory expertise that AI cannot reliably supply.
Who is responsible when AI-generated pharma content breaks the rules?
The pharmaceutical company whose product is being promoted bears legal and regulatory responsibility for AI-generated content, exactly as it does for content produced by any other means. The ABPI Code, FDA regulations, and equivalent frameworks in other markets do not distinguish between human-written and AI-generated materials: the obligation to ensure accuracy, balance, and compliance rests with the company, not the tool.
This is a critical point that enthusiasm for AI efficiency can obscure. If an AI system produces a promotional claim that overstates efficacy and that claim reaches a healthcare professional without adequate review, the company is accountable. The AI vendor may carry contractual liability for tool performance, but regulatory and reputational consequences fall on the pharmaceutical company.
In practice, accountability must be built into the workflow rather than assumed to sit with the technology. Every piece of AI-assisted promotional content still requires sign-off from qualified medical, legal, and regulatory reviewers. The MLR process does not disappear because AI was involved in drafting — if anything, reviewers need to apply heightened scrutiny to AI output, precisely because the errors it makes can be subtle and linguistically convincing.
How are pharma companies currently using AI for marketing materials?
In 2026, pharma companies are using AI for promotional and marketing materials in ways that range from cautious experimentation to structured, governance-backed deployment. The most common applications sit in content operations rather than content strategy: using AI to do more with approved assets rather than to generate new scientific or promotional claims.
Several large pharmaceutical companies have built internal content hubs that use AI to manage modular content libraries, enabling sales and marketing teams to assemble compliant materials from pre-approved building blocks without triggering a full MLR cycle for every piece. Others are using AI-powered personalisation engines to serve different versions of approved digital content to different HCP audiences based on specialty, prescribing behaviour, or engagement history.
On the agency side, AI is increasingly used in the early creative and briefing process — generating structural options, headline variants, or narrative frameworks that human strategists and writers then develop and refine. Medical communications agencies are also exploring AI for scientific literature monitoring, competitive intelligence, and rapid synthesis of congress data for internal briefing documents.
What is less common, and considerably more contested, is using AI to generate promotional claims or clinical content that goes directly into MLR review without substantial human authorship. The regulatory risk profile of that approach remains high, and most companies with mature AI governance frameworks are deliberately conservative about where in the content lifecycle AI output is trusted without significant human intervention.
What should pharma companies put in place before adopting AI for promotion?
Before deploying AI for pharmaceutical promotional content, companies need a governance framework that addresses accountability, review processes, data quality, and risk tolerance. Adopting AI without these foundations creates compliance exposure that outweighs the efficiency gains.
- A clear policy on AI use in promotional content: Defining which tasks AI may support, which require human authorship, and where AI output is prohibited from entering the MLR process without full human review
- Approved content anchoring: Ensuring any AI tool used for promotional drafting is connected to, and constrained by, verified, approved sources such as the SmPC and the approved claims matrix
- Trained reviewers: MLR teams who understand how AI generates content, what its characteristic failure modes are, and how to identify AI-introduced errors that might not be obvious to reviewers accustomed to human-authored drafts
- Audit trails: Documentation of AI involvement in content creation, including the prompts used, the model version, and the human review steps applied before final approval
- Vendor due diligence: Rigorous assessment of any third-party AI platform, including data security, training data provenance, and contractual clarity on liability
- Pilot before scale: Testing AI tools on lower-risk content types — internal briefings, non-promotional disease education, or content adaptation — before applying them to promotional materials that will reach HCPs or patients
The companies seeing the most value from AI in promotional content are those that treated governance as the first investment, not an afterthought. The technology is capable; the question is whether the organisational infrastructure around it is equally capable of catching what the technology gets wrong.
How Wizzard helps pharma brands navigate AI in promotional content
We work with pharmaceutical companies, biotech startups, and healthcare organisations to develop promotional and medical communications that are scientifically grounded, creatively ambitious, and built within the regulatory frameworks that govern each market. For clients exploring AI in their content operations, we bring both the creative and compliance perspective to the conversation — helping you identify where AI genuinely adds value and where human expertise remains essential.
- Strategic guidance on where AI can accelerate content production without increasing regulatory risk
- Human-led medical writing and creative development that AI tools support rather than replace
- Modular content architecture that enables compliant personalisation at scale
- Integrated medical affairs, commercial, and patient engagement communications developed by experienced in-house teams
- A “science seen creatively” approach that ensures promotional materials are as compelling as they are accurate
If your organisation is working through how to integrate AI responsibly into pharmaceutical promotion, speak to our team about building a content strategy that is both efficient and compliant.